碳离子放疗在胰腺癌中的临床数据综述
本文综述碳离子放疗用于胰腺癌的临床证据与现状。多数胰腺癌患者诊断时不可切除,局部晚期或交界可切除缺乏明确最佳方案;光子放疗的生存获益证据不足。日本I/II期试验的显著结果引发全球关注,多项研究正在验证该疗法。
要点
- 胰腺癌多数诊断时不可切除,局部晚期/交界可切除缺乏明确最佳方案
- 光子放疗联合化疗可改善局部控制,但无手术切除时总生存获益证据不足
- 日本I/II期碳离子放疗试验结果显著,多项验证性研究已启动
核心结论
- 碳离子放疗在胰腺癌中显示出值得关注的早期临床结果,但需更多研究验证。
- 不可切除胰腺癌亟需改进治疗方案,碳离子放疗是潜在方向之一。
研究设计与样本
- 本文为叙述性综述,汇总碳离子放疗在胰腺癌中的临床证据与当前应用。
主要发现
- 日本I/II期碳离子放疗试验在胰腺癌中取得显著结果并引发全球关注。
- 多项研究已启动以验证和强化碳离子放疗这一方向。
- 化疗、光子放疗及其联合可改善局部控制率,但无手术切除时总生存获益证据不足。
临床怎么用
- 对不可切除胰腺癌,碳离子放疗可作为研究背景下的探索性选择。
- 局部晚期或交界可切除胰腺癌尚无明确最佳方案,需个体化决策。
局限性
- 综述类文章,未提供原始研究的具体样本量、剂量及统计数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite all efforts, pancreatic cancer remains a highly lethal disease. Only surgical resection offers a realistic chance of survival. But at diagnosis the majority of patients suffer from unresectable disease. Whereas guidelines clearly recommend systemic treatments in metastatic disease, data is limited to support a specific treatment option for locally advanced or borderline resectable pancreatic cancer. Therefore, there is an urgent need to improve treatment schemes addressing patients that suffer from unresectable pancreatic cancer. Chemotherapy, photon radiotherapy and combinations of both have shown improved local control rates but there is still a lack of evidence demonstrating an overall survival benefit of photon radiotherapy if no surgical resection is achieved. Impressive results of Japanese Phase I/II-trials investigating carbon ion radiotherapy in pancreatic cancer attracted global attention. Several studies have been initiated to validate and intensify this promising issue. This review gives an overview of the evidence and current use of carbon ion radiotherapy in pancreatic cancer.
引用
- Liermann J, Shinoto M, Syed M, et al. Carbon ion radiotherapy in pancreatic cancer: A review of clinical data. Radiother Oncol. 2020. PMID: 32416281. doi:10.1016/j.radonc.2020.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。